France· FR:68452994
TEPEZZA 500 mg, poudre pour solution à diluer pour perfusion
A medicinal product containing téprotumumab, registered in France by AMGEN EUROPE.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TÉPROTUMUMAB
- Manufacturer
- AMGEN EUROPE
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009551081221 flacon(s) en verre avec fermeture à témoin d'effraction de 20 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Téprotumumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsTEPEZZA 500 mg poeder voor concentraat voor oplossing voor infusieAmgen Europe B.V.
- United StatesTEPEZZAHorizon Therapeutics USA, Inc.
- SwitzerlandTepezza 500 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaTEPEZZAAmgen Europe B.V., Breda
- SpainTEPEZZA 500 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandTEPEZZAAmgen Europe B.V.
- United KingdomTepezza 500mg powder for concentrate for solution for infusion vialsAmgen Ltd
- BelgiumTepezza 500 mgAmgen Europe
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tepezza
- Norway · Tepezza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/addf2151-4cdc-4b3b-9dcc-a74ed39c03e2 GET /v1/drugs/addf2151-4cdc-4b3b-9dcc-a74ed39c03e2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68452994",
"date_amm": "2025-06-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/25/1941",
"substance": "TÉPROTUMUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about téprotumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.